CD274 and ovarian cancer: BET inhibitors are also being evaluated with immune checkpoint blockade: a phase Ib open label trial is currently testing BET inhibitor RO6870810 and atezolizumab (anti-PD-L1) in patients with advanced ovarian cancer or triple negative breast cancer, to be completed in July 2020 (NCT0329217).